---
title: "VK2735 in Chronic weight management: Phase of product development"
description: "Formulary evidence on VK2735 in Chronic weight management: Phase of product development. Topics: Regulatory status: Submission planned; NDA planned after VANQUISH phase 3 data expected in the second half of 2027, Launch: Anticipated about two and a half years after October 2026, Subcutaneous formulation: FDA Type C meeting and end-of-phase 2 meeting before phase 3, Subcutaneous formulation: VANQUISH phase 3 program initiation and enrollment, and 5 further topics. 9 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Submission planned; NDA planned after VANQUISH phase 3 data expected in the second half of 2027

> “In addition, as a company, we have not previously filed NDAs with the FDA or filed similar applications with other foreign regulatory agencies.”

Source: [Viking Therapeutics Form 10-Q third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm)

> “If we can put together something that might be suitable for submission with the initial NDA, we would do that.”
> “It's possible we might be able to incorporate something in the initial filing.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

> “VK2735 Subcutaneous: VANQUISH Phase 3 Overview”
> “Data Expected 2H27”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “VANQUISH Phase 3 trials in obesity and T2D fully enrolled with data expected in 2H27”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

> “During the third quarter, both VANQUISH studies continued to advance on track. The company expects these studies to be completed in 2027.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.1-2"></a>

### Launch: Anticipated about two and a half years after October 2026

> “We have a pretty solid commercial team, especially given that we're 2 and a half years out from potential launch.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

> “these resources will support the company's growing commercial operations, infrastructure and plans as it prepares for the potential commercial launch of VK2735.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.1-3"></a>

### Subcutaneous formulation: FDA Type C meeting and end-of-phase 2 meeting before phase 3

> “During the second quarter, Viking received written responses to a U.S. Food and Drug Administration (FDA) Type C meeting packet, submitted to the agency earlier in the quarter.”
> “The company has scheduled an End-of-Phase 2 meeting with the FDA during the fourth quarter, which will help inform next steps for the Phase 3 program.”

Source: [Viking Therapeutics third quarter 2024 results release (2024)](https://ir.vikingtherapeutics.com/2024-10-23-Viking-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update)

> “In the fourth quarter of 2024, the company completed an End-of-Phase 2 meeting with the FDA and received feedback on the proposed Phase 3 plans as well as the overall development program for VK2735.”

Source: [Viking Therapeutics fourth quarter 2024 results release (2025)](https://ir.vikingtherapeutics.com/2025-02-05-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.1-4"></a>

### Subcutaneous formulation: VANQUISH phase 3 program initiation and enrollment

> “today announced the initiation of the VANQUISH Phase 3 clinical program for VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.”

Source: [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

> “Based on the positive findings from the Phase 2 VENTURE study, and subsequent feedback from the U.S. Food and Drug Administration (FDA), the company advanced the subcutaneous formulation of VK2735 into Phase 3 development, initiating the VANQUISH Phase 3 registration program in June of last year.”
> “The VANQUISH-1 study enrolled approximately 4,500 patients within approximately five months of initiation. The VANQUISH-2 study enrolled approximately 1,000 patients within approximately 9 months of initiation.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.1-5"></a>

### Subcutaneous formulation: VANQUISH extension studies and timing of a supplemental application

> “Following completion of the 78-week treatment period in both VANQUISH studies, participants are eligible to enroll in extension studies, enabling them to continue their treatment for up to an additional 52 weeks.”
> “In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration. The company anticipates the results of the extension studies to be available in 2028.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “I'd say it's probably more likely that it would be a supplement later, but we don't know that for sure at this point.”
> “But it seems more likely that the VANQUISH extension data would be sort of a standalone package that would be a supplement later.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.1.1-6"></a>

### Oral formulation: end-of-phase 2 meeting with the FDA

> “Viking held an end-of-Phase 2 meeting with the FDA to discuss potential next steps for oral VK2735.”

Source: [Viking Therapeutics fourth quarter 2025 results release (2026)](https://ir.vikingtherapeutics.com/2026-02-11-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-Corporate-Update)

> “As far as the oral end-of-Phase II and the subQ end-of-Phase II, we're not going to get into the details of the discussions, but I'd say the feedback was consistent with what we heard from the end-of-Phase II for the subQ formulation.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “The FDA, we had an end-of-phase II meeting in the fourth quarter last year, and the FDA they pointed out risks going from phase II to phase III, but they were okay with it.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="topic-2.1.1-7"></a>

### Oral formulation: SUNRISE phase 3 program initiation and expected data timing

> “today announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “VK2735 Oral: SUNRISE Phase 3 Overview”
> “Data Expected 2028”
> “Initiated 4Q26”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.1-8"></a>

### Development history: first clinical studies of each formulation

> “In January 2022, we announced the initiation of a Phase 1 SAD and MAD clinical trial of VK2735.”
> “In March 2023, we announced the initiation of a Phase 1 clinical study to evaluate a novel oral formulation of VK2735.”

Source: [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm)

<a id="topic-2.1.1-9"></a>

### Expedited program designations

No evidence found.

<a id="topic-2.1.1-10"></a>

### Patent estate for the GLP-1 agonist program

> “As of September 30, 2026, for our GLP-1 program, we own four U.S. patents, additional patents in certain foreign jurisdictions, three PCT applications, and several patent applications in the U.S. and certain foreign jurisdictions.”

Source: [Viking Therapeutics Form 10-Q third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm)

| Subject matter | Pending applications | Issued patents | Nominal patent term |
| --- | --- | --- | --- |
| GLP-1 agonists, as of December 31, 2025 | “113” | “13” | “2042-2045” |

Source: [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
